23.60
Newamsterdam Pharma Company Nv Borsa (NAMS) Ultime notizie
What analysts say about NewAmsterdam Pharma Company N.V. stockRobust investment performance - PrintWeekIndia
What analysts say about NewAmsterdam Pharma Company N.V. Equity Warrant stockFree Bull & Bear Market Updates - PrintWeekIndia
How NewAmsterdam Pharma Company N.V. Equity Warrant stock performs during market volatility - Newser
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock split in the near futureBreakout profit opportunities - jammulinksnews.com
Arizona State Retirement System Buys New Shares in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) - Defense World
What drives NewAmsterdam Pharma Company N.V. stock priceRapid wealth creation - Autocar Professional
What makes NewAmsterdam Pharma Company N.V. stock price move sharplyMassive Gain Ideas - Newser
NewAmsterdam Pharma Company N.V. Equity Warrant Stock Analysis and ForecastHigh-impact stock picks - jammulinksnews.com
NewAmsterdam Pharma Company N.V. Stock Analysis and ForecastDouble-digit growth - jammulinksnews.com
What drives NewAmsterdam Pharma Company N.V. Equity Warrant stock priceHigh-yield capital appreciation - jammulinksnews.com
NewAmsterdam Pharma to Present Alzheimer’s Biomarker Data from BROADWAY Trial at AAIC 2025 - GlobeNewswire
Major Alzheimer's Discovery: Cardiovascular Drug Shows Promising Brain Health Benefits in 1,727 Patients - Stock Titan
Is NewAmsterdam Pharma Company N.V. Equity Warrant a good long term investmentExceptional return forecasts - Autocar Professional
Is NewAmsterdam Pharma Company N.V. a good long term investmentExplosive portfolio gains - jammulinksnews.com
why newamsterdam pharma company n.v. equity warrant stock attracts strong analyst attentionFree Risk Assessment Services - Newser
When is the best time to buy NewAmsterdam Pharma Company N.V. stockFree Access to Investment Community - Newser
NewAmsterdam Pharma (NASDAQ:NAMS) Coverage Initiated at The Goldman Sachs Group - Defense World
How NewAmsterdam Pharma Company N.V. stock reacts to Fed policy changesFree Capital Allocation Plans - Newser
Goldman Sachs Initiates Coverage on NewAmsterdam Pharma With Neutral Rating, $27 Price Target - MarketScreener
Goldman Sachs initiates NewAmsterdam Pharma stock with Neutral rating By Investing.com - Investing.com South Africa
Goldman Sachs initiates NewAmsterdam Pharma stock with Neutral rating - Investing.com Australia
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):